MENU
+Compare
INTS
Stock ticker: NASDAQ
AS OF
Jul 22, 01:02 PM (EDT)
Price
$0.31
Change
-$0.01 (-3.12%)
Capitalization
8.3M

INTS Intensity Therapeutics Forecast, Technical & Fundamental Analysis

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers... Show more

INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for INTS with price predictions
Jul 21, 2025

INTS in +5.91% Uptrend, rising for three consecutive days on July 14, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INTS advanced for three days, in of 85 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 10, 2025. You may want to consider a long position or call options on INTS as a result. In of 43 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 17 cases where INTS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INTS broke above its upper Bollinger Band on July 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly better than average price growth. INTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.876) is normal, around the industry mean (18.131). P/E Ratio (0.000) is within average values for comparable stocks, (58.574). INTS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.444). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (274.844).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

INTS is expected to report earnings to fall 27.27% to -15 cents per share on August 18

Intensity Therapeutics INTS Stock Earnings Reports
Q2'25
Est.
$-0.16
Q1'25
Missed
by $0.04
Q4'24
Missed
by $0.95
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.04
The last earnings report on May 13 showed earnings per share of -21 cents, missing the estimate of -18 cents. With 974.77K shares outstanding, the current market capitalization sits at 8.30M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CSBR8.030.02
+0.25%
Champions Oncology
RXO16.14-0.03
-0.19%
RXO
ESS285.00-2.02
-0.70%
Essex Property Trust
RNAZ9.69-0.25
-2.52%
TransCode Therapeutics Inc
MLAB67.97-2.08
-2.97%
Mesa Laboratories

INTS and Stocks

Correlation & Price change

A.I.dvisor tells us that INTS and GBIO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-2.03%
GBIO - INTS
29%
Poorly correlated
+3.62%
MRKR - INTS
29%
Poorly correlated
-10.00%
ACAD - INTS
28%
Poorly correlated
-1.24%
GPCR - INTS
27%
Poorly correlated
-5.82%
CCCC - INTS
27%
Poorly correlated
-2.16%
More